Category Archives: Cell Therapy

Cell Therapy News is an online publication and email newsletter dedicated to sharing the latest cell therapy, gene therapy, and regenerative medicine research.
Subscribe
Published weekly since 2002, Cell Therapy News is our longest running online publication. Our editorial team curates the top publications, reviews, and news on in vivo gene therapy, cell therapy, and immunotherapy research. With over 15,000 subscribers and followers across our website, email newsletter, and Twitter feed, we are proud to facilitate the communication of cutting-edge cell therapy innovations.

Successful Gene Therapy of Diamond-Blackfan Anemia in a Mouse Model and Human CD34+ Cord Blood Hematopoietic Stem Cells Using a Clinically Applicable Lentiviral Vector

Researchers observed that transduced ribosomal protein S19 (Rps19)-deficient bone marrow cells could reconstitute mice longterm and rescue the bone marrow failure and severe anemia observed in Rps19-deficient mice, with a low risk of mutagenesis and a highly polyclonal insertion site pattern.
[Haematologica]
Abstract
Bookmark

No account yet? Register

0
Share

Beyond Conventional Immune-Checkpoint Inhibition — Novel Immunotherapies for Renal Cell Carcinoma

Using the structure provided by the well-described cancer–immunity cycle, scientists outline the key steps required for a successful antitumour immune response in the context of renal cell carcinoma, and describe the development of promising new immunotherapies within the context of this framework.
[Nature Reviews Clinical Oncology]
Braun, D. A., Bakouny, Z., Hirsch, L., Flippot, R., Van Allen, E. M., Wu, C. J., & Choueiri, T. K. (2021). Beyond conventional immune-checkpoint inhibition — novel immunotherapies for renal cell carcinoma. Nature Reviews Clinical Oncology, 1–16. https://doi.org/10.1038/s41571-020-00455-z Cite
Abstract
Bookmark

No account yet? Register

0
Share

Nanomaterials for T-Cell Cancer Immunotherapy

Scientists present an overview of nanomaterials that have been used to overcome clinical barriers to T-cell-based immunotherapies and provide their outlook of this emerging field at the interface of cancer immunotherapy and nanomaterial design.
[Nature Nanotechnology]
Gong, N., Sheppard, N. C., Billingsley, M. M., June, C. H., & Mitchell, M. J. (2021). Nanomaterials for T-cell cancer immunotherapy. Nature Nanotechnology, 16(1), 25–36. https://doi.org/10.1038/s41565-020-00822-y Cite
Full Article
Bookmark

No account yet? Register

0
Share

Pfizer Doses First Participant in Phase III Study for Duchenne Muscular Dystrophy Investigational Gene Therapy

Pfizer Inc. announced that the first participant has been dosed in the Phase III CIFFREO study, which will evaluate the efficacy and safety of investigational gene therapy candidate PF-06939926 in boys with Duchenne muscular dystrophy.
[Pfizer Inc.]
Press Release
Bookmark

No account yet? Register

0
Share

CXCR5 CAR-T Cells Simultaneously Target B Cell Non-Hodgkin’s Lymphoma and Tumor-Supportive Follicular T Helper Cells

To target both B cell Non-Hodgkin’s lymphoma and follicular T helper cells in the tumor microenvironment, researchers applied a chimeric antigen receptor that recognized human CXCR5 with high avidity.
[Nature Communications]
Bunse, M., Pfeilschifter, J., Bluhm, J., Zschummel, M., Joedicke, J. J., Wirges, A., Stark, H., Kretschmer, V., Chmielewski, M., Uckert, W., Abken, H., Westermann, J., Rehm, A., & Höpken, U. E. (2021). CXCR5 CAR-T cells simultaneously target B cell non-Hodgkin’s lymphoma and tumor-supportive follicular T helper cells. Nature Communications, 12(1), 240. https://doi.org/10.1038/s41467-020-20488-3 Cite
Full Article
Bookmark

No account yet? Register

0
Share

CRISPR Technologies for Precise Epigenome Editing

The authors review the state of currently achievable epigenetic manipulations along with corresponding applications. With future optimization, CRISPR-based epigenomic editing stands as a set of powerful tools for understanding and controlling biological function.
[Nature Cell Biology]
Nakamura, M., Gao, Y., Dominguez, A. A., & Qi, L. S. (2021). CRISPR technologies for precise epigenome editing. Nature Cell Biology, 23(1), 11–22. https://doi.org/10.1038/s41556-020-00620-7 Cite
Abstract
Bookmark

No account yet? Register

0
Share

Dynamic Immune Profiling Identifies the Stronger Graft-Versus-Leukemia (GVL) Effects With Haploidentical Allografts Compared to HLA-Matched Stem Cell Transplantation

Researchers employed two nonirradiated leukemia mouse models which carried human AML-ETO or MLL-AF9 fusion gene to establish haplo-identical and major histocompatibility-matched transplantation models and investigated the immune cell dynamic response during leukemia development in vivo.
[Cellular & Molecular Immunology]
Guo, H., Chang, Y.-J., Hong, Y., Xu, L.-P., Wang, Y., Zhang, X.-H., Wang, M., Chen, H., Chen, Y.-H., Wang, F.-R., Wei-Han, Sun, Y.-Q., Yan, C.-H., Tang, F.-F., Mo, X.-D., Liu, K.-Y., & Huang, X.-J. (2021). Dynamic immune profiling identifies the stronger graft-versus-leukemia (GVL) effects with haploidentical allografts compared to HLA-matched stem cell transplantation. Cellular & Molecular Immunology, 1–14. https://doi.org/10.1038/s41423-020-00597-1 Cite
Abstract
Bookmark

No account yet? Register

0
Share

CRISPR/Cas9 Directed to the Ube3a Antisense Transcript Improves Angelman Syndrome Phenotype in Mice

Scientists showed that gene editing of Ube3a-ATS in the mouse brain resulted in the formation of base pair insertions/deletions in neurons and the subsequent unsilencing of the paternal Ube3a allele in neurons, which partially corrected the behavior phenotype of a murine Angelman syndrome model.
[Journal of Clinical Investigation]
Schmid, R. S., Deng, X., Panikker, P., Msackyi, M., Breton, C., & Wilson, J. M. (2021). CRISPR/Cas9 directed to the Ube3a antisense transcript improves Angelman syndrome phenotype in mice. The Journal of Clinical Investigation. https://doi.org/10.1172/JCI142574 Cite
AbstractFull ArticleGraphical Abstract
Bookmark

No account yet? Register

0
Share

A Modular and Controllable T Cell Therapy Platform for Acute Myeloid Leukemia

Researchers developed a modular and controllable MHC-unrestricted adoptive T cell therapy platform tailored to acute myeloid leukemia.
[Leukemia]
Benmebarek, M.-R., Cadilha, B. L., Herrmann, M., Lesch, S., Schmitt, S., Stoiber, S., Darwich, A., Augsberger, C., Brauchle, B., Rohrbacher, L., Oner, A., Seifert, M., Schwerdtfeger, M., Gottschlich, A., Rataj, F., Fenn, N. C., Klein, C., Subklewe, M., Endres, S., … Kobold, S. (2021). A modular and controllable T cell therapy platform for acute myeloid leukemia. Leukemia, 1–15. https://doi.org/10.1038/s41375-020-01109-w Cite
Full Article
Bookmark

No account yet? Register

0
Share

U2af1 Is Required for Survival and Function of Hematopoietic Stem/Progenitor Cells

Using a novel conditional U2af1 knockout allele, investigators found that deletion of U2af1 results in profound defects in hematopoiesis characterized by pancytopenia, ablation of hematopoietic stem/progenitor cells leading to bone marrow failure and early lethality in mice.
[Leukemia]
Dutta, A., Yang, Y., Le, B. T., Zhang, Y., Abdel-Wahab, O., Zang, C., & Mohi, G. (2021). U2af1 is required for survival and function of hematopoietic stem/progenitor cells. Leukemia, 1–17. https://doi.org/10.1038/s41375-020-01116-x Cite
Abstract
Bookmark

No account yet? Register

0
Share

Overcoming Target Epitope Masking Resistance that Can Occur on Low-Antigen-Expresser AML Blasts after IL-1RAP Chimeric Antigen Receptor T Cell Therapy Using the Inducible Caspase 9 Suicide Gene Safety Switch

As acute myeloid leukemia (AML) primary blasts express different levels of accessory protein of the interleukin-1 receptor (IL-1RAP), scientists modeled transduction of different AML tumor cell lines screened for density of antigenic sites with their lentiviral vectors carrying a third-generation IL-1RAP chimeric antigen receptor, an iCASP9 suicide gene, and a truncated CD19 surface gene.
[Cancer Gene Therapy]
Warda, W., Da Rocha, M. N., Trad, R., Haderbache, R., Salma, Y., Bouquet, L., Roussel, X., Nicod, C., Deschamps, M., & Ferrand, C. (2021). Overcoming target epitope masking resistance that can occur on low-antigen-expresser AML blasts after IL-1RAP chimeric antigen receptor T cell therapy using the inducible caspase 9 suicide gene safety switch. Cancer Gene Therapy, 1–11. https://doi.org/10.1038/s41417-020-00284-3 Cite
Full Article
Bookmark

No account yet? Register

0
Share
Share